Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public

Added by pmartino
Group name EquipePM
Item Type Journal Article
Title Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15): a randomised, phase 3 study
Creator Goéré et al.
Author Olivier Glehen
Author Jean-Marc Guilloit
Author Jean-Marc Bereder
Author Gérard Lorimier
Author Emilie Thibaudeau
Author Laurent Ghouti
Author Amandine Pinto
Author Jean-Jacques Tuech
Author Reza Kianmanesh
Author Michel Carretier
Author Frédéric Marchal
Author Catherine Arvieux
Author Cécile Brigand
Author Pierre Meeus
Author Patrick Rat
Author Sylvaine Durand-Fontanier
Author Pascale Mariani
Author Zaher Lakkis
Author Valeria Loi
Author Nicolas Pirro
Author Charles Sabbagh
Author Matthieu Texier
Author Dominique Elias
Abstract BACKGROUND: Diagnosis and treatment of colorectal peritoneal metastases at an early stage, before the onset of signs, could improve patient survival. We aimed to compare the survival benefit of systematic second-look surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC), with surveillance, in patients at high risk of developing colorectal peritoneal metastases. METHODS: We did an open-label, randomised, phase 3 study in 23 hospitals in France. Eligible patients were aged 18-70 years and had a primary colorectal cancer with synchronous and localised colorectal peritoneal metastases removed during tumour resection, resected ovarian metastases, or a perforated tumour. Patients were randomly assigned (1:1) to surveillance or second-look surgery plus oxaliplatin-HIPEC (oxaliplatin 460 mg/m2, or oxaliplatin 300 mg/m2 plus irinotecan 200 mg/m2, plus intravenous fluorouracil 400 mg/m2), or mitomycin-HIPEC (mitomycin 35 mg/m2) alone in case of neuropathy, after 6 months of adjuvant systemic chemotherapy with no signs of disease recurrence. Randomisation was done via a web-based system, with stratification by treatment centre, nodal status, and risk factors for colorectal peritoneal metastases. Second-look surgery consisted of a complete exploration of the abdominal cavity via xyphopubic incision, and resection of all peritoneal implants if resectable. Surveillance after resection of colorectal cancer was done according to the French Guidelines. The primary outcome was 3-year disease-free survival, defined as the time from randomisation to peritoneal or distant disease recurrence, or death from any cause, whichever occurred first, analysed by intention to treat. Surgical complications were assessed in the second-look surgery group only. This study was registered at ClinicalTrials.gov, NCT01226394. FINDINGS: Between June 11, 2010, and March 31, 2015, 150 patients were recruited and randomly assigned to a treatment group (75 per group). After a median follow-up of 50ˇ8 months (IQR 47ˇ0-54ˇ8), 3-year disease-free survival was 53% (95% CI 41-64) in the surveillance group versus 44% (33-56) in the second-look surgery group (hazard ratio 0ˇ97, 95% CI 0ˇ61-1ˇ56). No treatment-related deaths were reported. 29 (41%) of 71 patients in the second-look surgery group had grade 3-4 complications. The most common grade 3-4 complications were intra-abdominal adverse events (haemorrhage, digestive leakage) in 12 (23%) of 71 patients and haematological adverse events in 13 (18%) of 71 patients. INTERPRETATION: Systematic second-look surgery plus oxaliplatin-HIPEC did not improve disease-free survival compared with standard surveillance. Currently, essential surveillance of patients at high risk of developing colorectal peritoneal metastases appears to be adequate and effective in terms of survival outcomes. FUNDING: French National Cancer Institute.
Publication The Lancet. Oncology
Date Jul 24, 2020
Journal Abbr Lancet Oncol.
Language eng
DOI 10.1016/S1470-2045(20)30322-3
ISSN 1474-5488
Short Title Second-look surgery plus hyperthermic intraperitoneal chemotherapy versus surveillance in patients at high risk of developing colorectal peritoneal metastases (PROPHYLOCHIP-PRODIGE 15)
Library Catalog PubMed
Extra 00001 PMID: 32717180
Tags Adolescent, Adult, Aged, clinic, Colorectal Neoplasms, Disease-Free Survival, Female, Fluorouracil, Humans, Hyperthermia, Induced, Leucovorin, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Peritoneal Neoplasms, Risk Factors, Second-Look Surgery, Young Adult
Date Added 2020/08/17 - 10:34:55
Date Modified 2021/03/05 - 10:38:35
Notes and Attachments PubMed entry (Attachment)
PubMed entry (Attachment)


© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés